SciSparc Common Stock Net 2017-2024 | SPRC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

SciSparc common stock net from 2017 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

SciSparc common stock net from 2017 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.7B
Takeda Pharmaceutical (TAK)	$42.4B
Sandoz Group AG (SDZNY)	$19.3B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.4B
Summit Therapeutics (SMMT)	$13.6B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$11.8B
Catalent (CTLT)	$10.8B
Jazz Pharmaceuticals (JAZZ)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$7.2B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$5.9B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.3B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Soleno Therapeutics (SLNO)	$2.4B
Arrowhead Pharmaceuticals (ARWR)	$2.3B
Centessa Pharmaceuticals (CNTA)	$2.1B
Evotec AG (EVO)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.7B
Recursion Pharmaceuticals (RXRX)	$1.6B
Harrow (HROW)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Cassava Sciences (SAVA)	$1.5B